Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 10, 2018 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Initiates Phase I First-in-Human Study of ACH-5548, a Third Oral Small Molecule Inhibitor of Complement Factor D

- Additional clinical compounds expand factor D portfolio opportunities - NEW HAVEN, Conn., July 10, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a clinical-stage...
June 14, 2018 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion to Present at the 2018 JMP Securities Life Sciences Conference

NEW HAVEN, Conn., June 14, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Joseph Truitt, President and Chief Executive Officer of Achillion, will present...
May 11, 2018 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Announces Upcoming Scientific Presentations at the 55th ERA-EDTA Congress

- Oral presentation discussing ACH-4471 and interim biomarker data from the ongoing 14-day Phase 2 study in C3G - - Poster presentation detailing in vitro data showing no significant reduction in...
May 04, 2018 06:35 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion to Present at the Deutsche Bank 43rd Annual Health Care Conference

NEW HAVEN, Conn., May 04, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Joseph Truitt, President and Chief Executive Officer of Achillion, will present...
May 02, 2018 06:35 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Reports First Quarter 2018 Financial Results and Management Transition

- Plans for clinical data in C3 glomerulopathy (C3G) and for paroxysmal nocturnal hemoglobinuria (PNH) remain on track for 2018 - - Joseph Truitt appointed Chief Executive Officer - NEW HAVEN,...
March 08, 2018 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion to Present at the Barclays Global Healthcare Conference

NEW HAVEN, Conn., March 08, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., Chief Executive Officer of Achillion, will present a...
February 28, 2018 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Raises Awareness for C3 Glomerulopathy With Launch of WeC3G™ Initiative as Part of Rare Disease Day 2018

February 28, 2018 is the 11th Annual Rare Disease Day Achillion sponsors initiative to help shine the light on C3G to raise awareness and understanding of this rare, chronic disease affecting the...
February 26, 2018 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Announces ACH-4471 Receives Positive Opinion for Orphan Drug Designation in the European Union for the Treatment of C3 Glomerulopathy

NEW HAVEN, Conn., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a biopharmaceutical company focused on advancing small molecule factor D inhibitors to modulate the...
February 22, 2018 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Announces Restructuring to Advance Corporate Strategy; Announces 2017 Fourth Quarter and Full Year Financial Results

Corporate restructuring expected to enable Achillion to focus on goal of advancing its clinical and late-stage preclinical portfolio while maintaining a strong balance sheet Joseph Truitt, Chief...
February 09, 2018 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion to Present at the Leerink Partners 7th Annual Global Healthcare Conference

NEW HAVEN, Conn., Feb. 09, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion,...